Symptoms

Study: Paxlovid cuts hospitalization, death only in at-risk COVID patients with weak immune systems seb_ra / iStock CIDRAP

...in JAMA Network Open, an observational Canadian study ties the antiviral drug combo nirmatrelvir-ritonavir (Paxlovid) to a lower risk of hospitalization or death only in very high-risk COVID-19 patients with weakened immune systems.

...

Why It's Too Soon to Call It Covid Season | WIRED

...experts on the front lines and doing data analysis say it’s too soon to declare that Covid has achieved seasonality. Looking back over the previous three years, they do see patterns: a spike at some point in the summer, such as the arrival of the Delta variant in 2021, and a spike sometime in the late fall or winter, such as the Thanksgiving surge of Omicron later that year. But those spikes haven’t occurred at the exact same time from year to year, and it’s possible they didn’t all arise for the same reasons.

...

Patients with coronavirus disease 2019 (COVID-19) present increased risk for ischemic cardiovascular complications up to 1 year after infection. Although the systemic inflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely contributes to this increased cardiovascular risk, whether SARS-CoV-2 directly infects the coronary vasculature and attendant atherosclerotic plaques remains unknown.

...

A blood test for long Covid is possible, new research suggests Scientists can now show key differences in the blood of those who recover from Covid — and those who don't. NBC News

...

Scientists have found clear differences in the blood of people with long Covid — a key first step in the development of a test to diagnose the illness.